HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 13 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Keymed Biosciences (2162.HK) - The $1.2B Deal with AstraZeneca for ADC and the Logic Behind

JD Health (6618.HK) - It's Time to Reassess the Business Prospects and Valuation

China Healthcare Weekly (Mar.10)- Three Conditions to Be Biopharma, Anticipate the Collapse, DS-8201

Keymed Biosciences (2162.HK) - The Potential for Doubling Valuation and the Corresponding Risks

Remegen Co Ltd (9995.HK) - There's Expectation Difference in Valuation; Trading Opportunity Occurs

Jacobio Pharmaceuticals Placement (1167.HK) - We Keep Hope for Jacobio Because of Dr. Wang Yinxiang

China Traditional Chinese Medicine (570.HK) - The Privatization Rumor and the Outlook

Equity Bottom-Up

<ul>
<li>Keymed is one of the few enterprises we believe have the strength to develop FIC in the future. Keymed's "pragmatic" in terms of commercialization,which set it apart from other biotech.</li>
<li>The current valuation is expensive based on our forecast. The expansion potential of future valuation depends on the progress of overseas R&amp;D/commercialization. This is where Keymed really takes off.</li>
<li>One big reason we've been positive about Keymed is because of its founder, Chen Bo. The down-to-earth style of management makes us full of expectations for <a href="https://www.smartkarma.com/entities/keymed-biosciences-inc" target="_blank" data-smartkarma-citation="entities:33011:1" rel="noopener">Keymed Biosciences (2162 HK)</a>.</li>
</ul>


Keymed is one of the few enterprises we believe have the strength to develop FIC in the future. Keymed's "pragmatic" in terms of commercialization,which set it apart from other biotech.
The current valuation is expensive based on our forecast. The expansion potential of future valuation depends on the progress of overseas R&amp;D/commercialization. This is where Keymed really takes off.
One big reason we've been positive about Keymed is because of its founder, Chen Bo. The down-to-earth style of management makes us full of expectations for Keymed Biosciences (2162 HK).


Keymed Biosciences (2162.HK) - We Have High Hopes for Keymed, but Valuation Is Expensive